Tom Götze

Tom Götze

Auto-generated profile, based on publicly available information

Tom Götze

Faculty of Chemistry and Mineralogy Leipzig University Johannisallee 29 Leipzig 04103 Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in ChemMedChem
Verified
Journal Article
Open access
AKAleksandr Kazimir
Aleksandr Kazimir
TGTom Götze
Tom Götze
PLPeter Lönnecke
Peter Lönnecke
BMBlagoje Murganić
Blagoje Murganić
SMSanja Mijatović
Sanja Mijatović
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins
Triple‐negative breast cancer (TNBC) poses challenges in therapy due to the absence of target expression such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Frequently, the treatment of TNBC involves the combination of several therapeutics. However, an enhanced therapeutic effect can be also achieved within a single molecule. The efficacy of raloxifene can be improved by designing a raloxifene‐based hybrid drug bearing a 2,2’‐bipyridine moiety (2). Integration of platinum(II), palladium(II), and nickel(II) complexes into this structure dramatically changed the cytotoxicity. The platinum(II) dichloride complex 3 did not demonstrate any activity, while palladium(II) and nickel(II) dichloride complexes 4 and 5 exhibited various cytotoxic behavior towards different types of hormone‐receptor positive (HR+) cancer and TNBC cell lines. The replacement of the two chlorido ligands in 3–5 with a dicarbollide (carborate) ion [C2B9H11]2− resulted in reduced activity of compounds 6, 7, and 8. However, the palladacarborane complex 7 demonstrated higher selectivity towards TNBC. Furthermore, the mechanism of action was shifted from cytotoxic to explicitly cytostatic with detectable proliferation arrest and accelerated aging, characterized by senescence‐associated phenotype of TNBC cells. This study provides valuable insights into the development of hybrid therapeutics against TNBC.

3 April 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
AKAleksandr Kazimir
Aleksandr Kazimir
TGTom Götze
Tom Götze
BMBlagoje Murganić
Blagoje Murganić
SMSanja Mijatović
Sanja Mijatović
DMDanijela Maksimović-Ivanić
Danijela Maksimović-Ivanić
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins
Raloxifene, a selective oestrogen receptor modulator (SERM), has demonstrated efficacy in the prevention and therapy of oestrogen receptor-positive (ER+) breast cancer, with some degree of effectiveness against triple-negative forms. This suggests the presence of oestrogen receptor-independent pathways in raloxifene-mediated anticancer activity. To enhance the potential of raloxifene against the most aggressive breast cancer cells, hybrid molecules combining the drug with a metal chelator moiety have been developed. In this study, we synthetically modified the structure of raloxifene by incorporating a 2,2′-bipyridine (2,2′-bipy) moiety, resulting in [6-methoxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl]-[4-(2,2′-bipyridin-4′-yl-methoxy)phenyl]methanone (bipyraloxifene). We investigated the cytotoxic activity of both raloxifene and bipyraloxifene against ER+ breast adenocarcinomas, glioblastomas, and a triple-negative breast cancer (TNBC) cell line, elucidating their mode of action against TNBC. Bipyraloxifene maintained a mechanism based on caspase-mediated apoptosis but exhibited significantly higher activity and selectivity compared to the original drug, particularly evident in triple-negative stem-like MDA-MB-231 cells.


1 September 2021 in Annals of Oncology
Verified
Journal Article
Closed access
Arndt VogelArndt Vogel
Arndt Vogel
DBD.M. Behringer
D.M. Behringer
SBS. Bröckling
S. Bröckling
JCJ. Chater
J. Chater
HDH-G. Derigs
H-G. Derigs
SAS-E. Al-Batran
S-E. Al-Batran

1 January 2022 in ChemViews
Verified
Journal Article
Closed access
KAKen Luca Abel
Ken Luca Abel
TGTom Götze
Tom Götze
DHDomenique Herbstritt
Domenique Herbstritt
MHMaria Annette Herz
Maria Annette Herz
JLJonathan Lebelt
Jonathan Lebelt
PRPascal L. Roßberg
Pascal L. Roßberg